Skip to main content
University of California San Francisco
UCSF School of Medicine | Department of Pediatrics UCSF Medical Center

Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.

  • Read more about Impact of Two Measures of Micrometastatic Disease on Clinical Outcomes in Patients with Newly Diagnosed Ewing Sarcoma: A Report from the Children's Oncology Group.

Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

  • Read more about Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors.

Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.

  • Read more about Spinal Myxopapillary Ependymomas Demonstrate a Warburg Phenotype.

Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

  • Read more about Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma.

BET bromodomain inhibition of MYC-amplified medulloblastoma.

  • Read more about BET bromodomain inhibition of MYC-amplified medulloblastoma.

Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

  • Read more about Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.

It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.

  • Read more about It takes two to tango: Dual inhibition of PI3K and MAPK in rhabdomyosarcoma.

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

  • Read more about Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.

Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

  • Read more about Targeted isotretinoin in neuroblastoma: kinetics, genetics, or absorption.

Promising therapeutic targets in neuroblastoma.

  • Read more about Promising therapeutic targets in neuroblastoma.

Pagination

  • Previous page ‹‹
  • Page 3
  • Next page ››
Subscribe to Clinical cancer research : an official journal of the American Association for Cancer Research

Pediatrics Home

MAKE A GIFT

© 2026 The Regents of the University of California. The University of California San Francisco  |  UCSF Department of Pediatrics                                                                                   Accessibility  Privacy Policy  Terms of Use  A-Z Website List